Advances in conventional flow and image-assisted cytometry provide the instrumentation of choice for studies requiring quantitative analysis of DDR. Surprisingly, however, commonly used high-content approaches are still based on the static principle, yielding information on the cell status at a particular time point. Capabilities of high-speed, multiparameter and real-time analysis of small numbers of patient derived cells are still very limited (
Wlodkowic et al., 2010). The improvements in such capabilities are of particular importance for the development of personalized therapeutic approaches (point-of-care diagnostics) and the increasing role of cost and time savings in drug screening pipelines. Not surprisingly, enabling strategies that can reduce expenditures while at the same time increase throughput and content of information are attracting growing interest (
Wlodkowic et al., 2010;
Wlodkowic and Cooper, 2010).
The last decade, in particular, has brought some spectacular innovations in the field of miniaturized cytometric technologies that can open up new avenues for high-throughput DDR analysis. Namely, the up-and-coming microfluidic Lab-on-a-Chip (LOC) technology and the micro-total analysis systems (µTAS) are two of the most promising avenues for massively parallelized studies with single-cell resolution (
Whitesides, 2006;
El-Ali et al., 2006; Sims and Allbritton, 2006). The transfer of traditional bioanalytical methods to a microfabricated format provides a means to reduce drug screening expenditures while vastly increasing throughput and content of information from a given sample (
Manz and Dittrich, 2006). On the other hand, µTAS increase both the resolution of analysis while reducing the assay running costs (
Hong et al., 2009;
Kang et al., 2008). Most importantly, however, only small cell numbers and operational reagent volumes are required for microfabricated technologies as compared to the conventional counterparts such as e.g. flow cytometry (Sims and Allbritton, 2006;
Wlodkowic et al., 2009;
Wlodkowic and Cooper, 2010). By providing an alternative to expensive instrumentation such as flow or laser scanning cytometers and sorters, user-friendly LOC technologies can prospectively enable routine DDR analysis on patient-derived specimens.
A number of emerging, microfluidic LOC technologies for cell-based assays has recently been reported such as microflow cytometry (µFCM), microfluorescently activated cell sorting (µFACS) and in-flow magnetically activated cell sorting (µMACS) that are all up-and-coming examples of miniaturized on-chip flow cytometric technologies with substantial potential in DDR analysis and personalized diagnostics (
Chan et al., 2003;
Wolff et al., 2003;
Fu et al., 2002;
Adams et al., 2008). Microfluidic chip-based cytometry is slowly entering a commercial phase with increasing numbers of user-friendly devices capable of multiparameter fluorescent analysis of cells and particles (
Wlodkowic et al., 2009;
Wlodkowic and Cooper, 2010). The most notable examples involve the CellLab Chip (Agilent Technologies, Santa Clara, CA, USA), Fishman-R (On-chip biotechnologies Co, Tokyo, Japan) and the Gigasort™ system (CytonomeST LLC, Boston, MA, USA) which all employ enclosed and disposable chip-based cartridges (
Chan et al., 2003;
Wlodkowic et al., 2009;
Takeda and Jimma, 2009;
Takao et al., 2009). These approaches are particularly attractive for the clinical and diagnostic laboratories as they allow rapid analysis of only small amounts of patient derived cells.
Technological foundations initially developed for DNA microarrays have recently provided the starting point for development of chemical, protein microarrays, carbohydrate and tissue microarrays (
Gomase et al., 2008;
Camp et al., 2008;
Ma and Horiuchi, 2006;
Uttamchandani and Yao, 2008). They all offer miniaturization, low reagent consumption, automation as well as qualitative and quantitative approaches to analyze gene and protein expression on a population level (
Sobek et al., 2006). They do, however, suffer from a lack of capabilities to monitor single living cells in real-time and as such represent a binary system that averages the results from every given cell while capturing a snap-shot of the intermittent cellular reaction (
Wlodkowic and Cooper, 2010;
Wlodkowic et al., 2010). These drawbacks have recently fueled the development of new technologies: the living cell microarrays and microfluidic cell arrays that advance the spatiotemporal control of biomolecules and cells (
Yarmush and King, 2009;
Wlodkowic and Cooper, 2010).
Cell microarrays in general allow creating positioned arrays composed of single living cells (
DiCarlo et al., 2006;
Tokimitsu et al., 2007;
Yamamura et al., 2005). Unlike flow cytometry, however, measurements are made at multiple time points, and in contrast to conventional time-lapse microscopy, image analysis is greatly simplified by arranging the cells in a spatially defined pattern and by their physical separation (
DiCarlo et al., 2006;
Wlodkowic et al., 2009;
Wlodkowic and Cooper, 2010). As such they are ideal for drug screening routines and scalable for constructing high-throughput screening platforms (
Wang et al., 2007). They also have the ability to perform kinetic and multivariate analysis of signaling events on a single cell level (
Wlodkowic et al., 2009;
Faley et al., 2009). Thus, cell microarray technology seems to be particularly suitable to uncover intricacies in cell-to-cell variability and its relevance to cancer therapy including the DDR analysis at a single cell resolution (
Wlodkowic and Cooper, 2010). In this context, our recent studies have validated the application of live-cell microarrays for the kinetic analysis of drug-induced programmed cell death in hematopoietic cancer cells and hematopoietic cancer stem cells (
Wlodkowic et al., 2009;
Faley et al., 2009). DDR analysis on living cell microarrays is a next logical example that can provide innovative diagnostic and screening applications.
We have recently postulated that the combination of microfluidic cell arrays with integrated on-chip gene delivery technology (geno
mics), functional and dynamic live-cell analysis (cyt
omics) and intracellular antibody staining of selected proteins (prote
omics) can provide innovative, multivariate assays for high-content data mining and enhanced elucidation of cell signaling pathways (
Wlodkowic et al., 2010;
Wlodkowic and Cooper, 2010). It is largely anticipated that advances in many innovative microfluidic technologies will provide innovative analytical tools for studies requiring quantitative analysis of the DDR.